PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-108.36%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-9873.13%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-16129.65%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-12933.18%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-12933.18%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
24.22%
Share count expansion well above CRVO's 1.28%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.22%
Diluted share count expanding well above CRVO's 1.28%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-18.12%
Negative OCF growth while CRVO is at 77.94%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
0.96%
FCF growth under 50% of CRVO's 77.94%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.71%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-63.71%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-2899.60%
Negative 3Y OCF/share CAGR while CRVO stands at 37.72%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-30244.22%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-30244.22%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-27789.91%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-195.85%
Negative equity/share CAGR over 10 years while CRVO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-195.85%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
20.77%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.33%
Negative asset growth while CRVO invests at 3.76%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
14.08%
Positive BV/share change while CRVO is negative. John Neff sees a clear edge over a competitor losing equity.
11.04%
Debt shrinking faster vs. CRVO's 23.40%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
35.15%
R&D growth of 35.15% while CRVO is zero. Bruce Berkowitz checks if the moderate investment leads to meaningful product differentiation.
3110.63%
SG&A growth well above CRVO's 13.33%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.